Evidence map›Paper›PMID 25908636›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2015

Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma.

Christina Michailidi, Stamatios Theocharis, Gerasimos Tsourouflis, Vasiliki Pletsa, Gregorios Kouraklis, Efstratios Patsouris, Athanasios G Papavassiliou, Constantinos Troungos

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Journal of clinical medicine · 2023
    Article
  9. Article
  10. Article
  11. Molecular characterization of colorectal cancer patientsBiomedica : revista del Instituto Nacional de Salud · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christina MichailidiDepartment of Biological Chemistry, University of Athens Medical School, Athens 11527, Greece.
Stamatios TheocharisFirst Department of Pathology, University of Athens Medical School, Athens 11527, Greece.
Gerasimos TsourouflisSecond Department of Propedeutic Surgery, University of Athens Medical School, Athens 11527, Greece.
Vasiliki PletsaInstitute of Biology, Medicinal Chemistry and Biotechnology, Division of Biological Research & Biotechnology, National Hellenic Research Foundation, Athens 11635, Greece.
Gregorios KouraklisSecond Department of Propedeutic Surgery, University of Athens Medical School, Athens 11527, Greece.
Efstratios PatsourisFirst Department of Pathology, University of Athens Medical School, Athens 11527, Greece.
Athanasios G PapavassiliouDepartment of Biological Chemistry, University of Athens Medical School, Athens 11527, Greece.
Constantinos TroungosDepartment of Biological Chemistry, University of Athens Medical School, Athens 11527, Greece ktrougkos@med.uoa.gr papavas@med.uoa.gr.
National and Kapodistrian University of Athens · GRNational Hellenic Research Foundation · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide. CRC development is the result of genetic and epigenetic alterations accumulation in the epithelial cells of colon mucosa. In the present study, DNA methylation, an epigenetic event, was evaluated in tumoral and matching normal epithelium in a cohort of 61 CRC patients. The results confirmed and expanded knowledge for the tumor suppressor genes hMLH1, MGMT, APC, and CDH1. Promoter methylation was observed for all the examined genes in different percentage. A total of 71% and 10% of the examined cases were found to be methylated in two or more and in all genes, respectively. mRNA and protein levels were also evaluated. Promoter methylation of hMLH1, MGMT, APC, and CDH1 genes was present at the early stages of tumor's formation and it could also be detected in the normal mucosa. Correlations of the methylated genes with patient's age and tumor's clinicopathological characteristics were also observed. Our findings suggest that DNA methylation is a useful marker for tumor progression monitoring and that promoter methylation in certain genes is associated with more advanced tumor stage, poor differentiation, and metastasis.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinomaAdenomatous Polyposis Coli ProteinAgedAntigens, CDCadherinsColonColonic NeoplasmsDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleGene Expression Regulation, NeoplasticHumansMaleMutL Protein Homolog 1Adaptor Proteins, Signal TransducingAdenomatous Polyposis Coli ProteinAntigens, CDAPC protein, humanCadherinsCDH1 protein, humanDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanMLH1 protein, humanMutL Protein Homolog 1Nuclear ProteinsTumor Suppressor ProteinsColon cancerCpG islandsepigeneticsmethylationmethylation-specific PCR

Identifiers

PMID25908636
PMCPMC4935349
OpenAlexW2088716532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.